Qualigen Therapeutics Overview
Latest P/E ratio for Qualigen Therapeutics: -0.12 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.12
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for QLGN is -0.12. That is below the Healthcare sector average of 25.3. Investors often review this figure alongside Qualigen Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, QLGN currently prints -0.12 for P/E ratio, while the sector average sits near 25.3. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at Qualigen Therapeutics's growth, margins, and balance sheet.
A P/E ratio of -0.12 for Qualigen Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (25.3) and with QLGN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting QLGN's P/E ratio (-0.12), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Qualigen Therapeutics's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
